Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kseniya Kobets

Dermatology Hackensack, NJ Medical Doctor

NPI 1912296674 CMS profile 358868

20 Prospect Ave Ste 702, Hackensack, NJ 07601

Open in the dashboard

General payments

$2,327

112 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kseniya Kobets of Hackensack, NJ is reported in the CMS Open Payments database as having received $2,327 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $374 8
2024 General $119 7
2023 General $353 6
2022 General $90 5
2021 General $20 1
2020 General $163 11
2019 General $1,209 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kseniya Kobets
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kseniya Kobets were reported at $374. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kseniya Kobets Dermatology median Middle half National median
2019 $1,209 $454 $129–$1,240 $163
2020 $163 $235 $81–$756 $114
2021 $20 $377 $108–$1,108 $132
2022 $90 $514 $143–$1,391 $149
2023 $353 $607 $159–$1,674 $160
2024 $119 $751 $204–$1,903 $164
2025 $374 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $401 23 payments
  2. Sun Pharmaceutical Industries Inc. $387 9 payments
  3. AbbVie, Inc. $222 7 payments
  4. Pfizer Inc. $214 14 payments
  5. Allergan Inc. $150 1 payment
  6. Journey Medical Corporation $134 4 payments
  7. Almirall LLC $113 8 payments
  8. Mayne Pharma Inc. $82 5 payments
  9. Biofrontera Inc. $77 5 payments
  10. Novartis Pharmaceuticals Corporation $63 3 payments
  11. Other $483 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,313 111 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Winlevi $387 9 payments
  2. EUCRISA $214 14 payments
  3. Absorica LD $160 3 payments
  4. BOTOX COSMETIC $150 1 payment
  5. SOOLANTRA $146 9 payments
  6. EPIDUO FORTE $139 13 payments
  7. TargaDox $134 4 payments
  8. Exelderm $134 4 payments
  9. Ximino $131 3 payments
  10. RINVOQ $125 1 payment
  11. Other $1,201 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

141

Median for Dermatology: 534

Drug cost

$2,510

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 36 $1,658
Ketoconazole Generic 31 $372
Triamcinolone Acetonide Generic 21 $200
Minoxidil Generic 18 $177
Hydrocortisone Generic 16 $71
Finasteride Generic 19 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$10,257

Medicare's payments for the services billed

Medicare patients

50

Average age 69

Services billed

149

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 56%
High blood pressure 48%
Depression 32%
Osteoporosis 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Winlevi
  • Sun Pharmaceutical Industries Inc. $80
$80 — —
SKYRIZI
  • AbbVie, Inc. $15
$15 — —
Cabtreo
  • Ortho Dermatologics, a division of Bausch Health US, LLC $15
$15 — —
Absorica LD
  • Sun Pharmaceutical Industries Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record